GlassScriptPhysician profile
Meriem Richardson
NPI 1518720333
$1,546.68
in general payments reported to CMS, 2019-2025
17 companies · $497 in 2025
The $497 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,050 · 2025: $497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,526 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,526.46 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $411.87 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Silk Road Medical, INC. | $180.35 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Bayer Healthcare Pharmaceuticals INC. | $152.16 | 2024-2025 | |
| Lilly USA, LLC | $137.34 | 2024-2025 | Jardiance, Zepbound, Mounjaro |
| Abbvie INC. | $111.41 | 2024-2025 | |
| Exact Sciences Corporation | $108.03 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $103.78 | 2024-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $77.58 | 2024-2025 | Trelegy Ellipta |
| Novo Nordisk INC | $61.41 | 2024-2025 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.28 | 2024 | Jardiance, Tradjenta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.91 | 2024 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $31.43 | 2024-2025 | Voquezna |
| Paratek Pharmaceuticals, INC. | $19.32 | 2024 | Nuzyra |
| Dexcom, INC. | $17.16 | 2024 | Dexcom G6 Transmitter |
| Pfizer INC. | $15.71 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $15.03 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $13.91 | 2024 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meriem Richardson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.